Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 10, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000880242 | |
Entity Registrant Name | BIOLARGO, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-19709 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 65-0159115 | |
Entity Address, Address Line One | 14921 Chestnut St. | |
Entity Address, City or Town | Westminster | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 92683 | |
City Area Code | 888 | |
Local Phone Number | 400-2863 | |
Title of 12(b) Security | Common stock | |
Trading Symbol | BLGO | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 275,417,050 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 1,268,000 | $ 962,000 |
Accounts receivable, net of allowance | 884,000 | 513,000 |
Inventories, net of allowance | 260,000 | 241,000 |
Prepaid expenses and other current assets | 120,000 | 85,000 |
Total current assets | 2,532,000 | 1,801,000 |
Non-current assets | ||
Equipment and leasehold improvements, net of depreciation | 196,000 | 61,000 |
Other non-current assets | 123,000 | 69,000 |
Investment in South Korean joint venture | 33,000 | 48,000 |
Right of use operating lease, net of amortization | 896,000 | 453,000 |
Clyra Medical prepaid marketing (Note 8) | 591,000 | 591,000 |
Total assets | 4,371,000 | 3,023,000 |
Current liabilities: | ||
Debt obligations, net of discount and amortization (Note 4) | 86,000 | 314,000 |
Contract liability | 6,000 | 89,000 |
Customer deposits | 109,000 | 79,000 |
Lease liability | 97,000 | 103,000 |
Total current liabilities | 1,029,000 | 1,374,000 |
Long-term liabilities: | ||
Long-term debt, noncurrent | 247,000 | 180,000 |
Lease liability | 799,000 | 349,000 |
Total long-term liabilities | 1,309,000 | 716,000 |
Total liabilities | 2,338,000 | 2,090,000 |
COMMITMENTS AND CONTINGENCIES (Note 10) | ||
STOCKHOLDERS’ EQUITY (DEFICIT): | ||
Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at September 30, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 274,622,640 and 255,893,726 Shares Issued, at September 30, 2022 and December 31, 2021 | 184,000 | 171,000 |
Additional paid-in capital | 147,470,000 | 143,718,000 |
Accumulated deficit | (142,505,000) | (139,121,000) |
Accumulated other comprehensive loss | (185,000) | (115,000) |
Total BioLargo Inc. and subsidiaries stockholders’ equity | 4,964,000 | 4,653,000 |
Non-controlling interest (Note 8) | (2,931,000) | (3,720,000) |
Total stockholders’ equity | 2,033,000 | 933,000 |
Total liabilities and stockholders’ equity | 4,371,000 | 3,023,000 |
Entities, Excluding Partially Owned Subsidiary [Member] | ||
Current liabilities: | ||
Accounts payable and accrued expenses | 520,000 | 559,000 |
Long-term liabilities: | ||
Long-term debt, noncurrent | 247,000 | 180,000 |
Partially Owned Subsidiary [Member] | ||
Current liabilities: | ||
Accounts payable and accrued expenses | 211,000 | 230,000 |
Long-term liabilities: | ||
Long-term debt, noncurrent | $ 263,000 | $ 187,000 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Convertible Preferred Stock, Par Value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Convertible Preferred Stock, Shares Authorized (in shares) | 50,000,000 | 50,000,000 |
Convertible Preferred Stock, Shares Issued (in shares) | 0 | 0 |
Convertible Preferred Stock, Shares Outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Common stock, shares authorized (in shares) | 550,000,000 | 550,000,000 |
Common stock, shares issued (in shares) | 274,622,640 | 255,893,726 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | ||||
Revenue from Contract with Customer, Including Assessed Tax | $ 1,500,000 | $ 712,000 | $ 3,786,000 | $ 1,743,000 |
Cost of revenue | ||||
Cost of Goods and Services Sold | (748,000) | (362,000) | (1,894,000) | (963,000) |
Gross profit | 752,000 | 350,000 | 1,892,000 | 780,000 |
Operating expenses | ||||
Selling, general and administrative expenses | 1,424,000 | 1,461,000 | 4,847,000 | 4,766,000 |
Research and development | 271,000 | 344,000 | 1,018,000 | 1,027,000 |
Total operating expenses | 1,695,000 | 1,805,000 | 5,865,000 | 5,793,000 |
Operating loss | (943,000) | (1,455,000) | (3,973,000) | (5,013,000) |
Other (expense) income: | ||||
Interest expense | (14,000) | (26,000) | (42,000) | (208,000) |
PPP loan forgiveness | 0 | 0 | 174,000 | 43,000 |
Tax credit | 66,000 | 21,000 | 66,000 | 50,000 |
Grant income | 44,000 | 25,000 | 51,000 | 25,000 |
Total other (expense) income: | 96,000 | 18,000 | 249,000 | (90,000) |
Net loss | (847,000) | (1,435,000) | (3,724,000) | (5,103,000) |
Net loss attributable to noncontrolling interest | (343,000) | (134,000) | (340,000) | (549,000) |
Net loss attributable to common shareholders | $ (504,000) | $ (1,301,000) | $ (3,384,000) | $ (4,554,000) |
Net loss per share attributable to common shareholders: | ||||
Loss per share attributable to shareholders – basic and diluted (in dollars per share) | $ 0 | $ (0.01) | $ (0.01) | $ (0.02) |
Weighted average number of common shares outstanding: (in shares) | 270,665,820 | 252,912,561 | 265,812,188 | 243,529,117 |
Comprehensive loss: | ||||
Net loss | $ (847,000) | $ (1,435,000) | $ (3,724,000) | $ (5,103,000) |
Foreign currency translation | (59,000) | (7,000) | (70,000) | (9,000) |
Comprehensive loss | (850,000) | (1,442,000) | (3,794,000) | (5,112,000) |
Comprehensive loss attributable to noncontrolling interest | (343,000) | (134,000) | (340,000) | (549,000) |
Comprehensive loss attributable to common stockholders | (507,000) | (1,308,000) | (3,454,000) | (4,563,000) |
Product [Member] | ||||
Revenues | ||||
Revenue from Contract with Customer, Including Assessed Tax | 1,216,000 | 431,000 | 2,532,000 | 1,190,000 |
Cost of revenue | ||||
Cost of Goods and Services Sold | (515,000) | (204,000) | (1,174,000) | (600,000) |
Service [Member] | ||||
Revenues | ||||
Revenue from Contract with Customer, Including Assessed Tax | 284,000 | 281,000 | 1,254,000 | 553,000 |
Cost of revenue | ||||
Cost of Goods and Services Sold | $ (233,000) | $ (158,000) | $ (720,000) | $ (363,000) |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Clyra Medical Technology Inc [Member] Common Stock [Member] | Clyra Medical Technology Inc [Member] Additional Paid-in Capital [Member] | Clyra Medical Technology Inc [Member] Retained Earnings [Member] | Clyra Medical Technology Inc [Member] AOCI Attributable to Parent [Member] | Clyra Medical Technology Inc [Member] Noncontrolling Interest [Member] | Clyra Medical Technology Inc [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 225,885,682 | |||||||||||
Balance at Dec. 31, 2020 | $ 151,000 | $ 135,849,000 | $ (132,041,000) | $ (101,000) | $ (4,093,000) | $ (235,000) | ||||||
Sale of common stock for cash (in shares) | 13,330,619 | |||||||||||
Sale of common stock for cash | $ 9,000 | 2,097,000 | 0 | 0 | 0 | 2,106,000 | ||||||
Issuance of common stock for service (in shares) | 747,487 | |||||||||||
Issuance of common stock for service | $ 1,000 | 110,000 | 0 | 0 | 0 | 111,000 | ||||||
Stock option compensation expense | $ 0 | $ 161,000 | $ 0 | $ 0 | $ 0 | $ 161,000 | 0 | 424,000 | 0 | 0 | 0 | 424,000 |
Noncontrolling interest allocation | 0 | (313,000) | 0 | 0 | 313,000 | 0 | ||||||
Net loss | 0 | 0 | (1,631,000) | 0 | (247,000) | (1,878,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | (2,000) | 0 | (2,000) | ||||||
Foreign currency translation | $ 0 | 0 | 0 | (2,000) | 0 | (2,000) | ||||||
Balance (in shares) at Mar. 31, 2021 | 239,963,788 | |||||||||||
Balance at Mar. 31, 2021 | $ 161,000 | 138,363,000 | (133,672,000) | (103,000) | (3,977,000) | 772,000 | ||||||
Warrants and conversion feature issued as discount on convertible note payable | $ 0 | 35,000 | 0 | 0 | 0 | 35,000 | ||||||
Clyra Medical securities offering | 0 | 0 | 0 | 0 | 50,000 | 50,000 | ||||||
Balance (in shares) at Dec. 31, 2020 | 225,885,682 | |||||||||||
Balance at Dec. 31, 2020 | $ 151,000 | 135,849,000 | (132,041,000) | (101,000) | (4,093,000) | (235,000) | ||||||
Net loss | (5,103,000) | |||||||||||
Foreign currency translation | (9,000) | |||||||||||
Foreign currency translation | (9,000) | |||||||||||
Balance (in shares) at Sep. 30, 2021 | 255,368,553 | |||||||||||
Balance at Sep. 30, 2021 | $ 171,000 | 141,343,000 | (136,595,000) | (110,000) | (3,806,000) | 1,003,000 | ||||||
Balance (in shares) at Dec. 31, 2020 | 225,885,682 | |||||||||||
Balance at Dec. 31, 2020 | $ 151,000 | 135,849,000 | (132,041,000) | (101,000) | (4,093,000) | (235,000) | ||||||
Balance (in shares) at Dec. 31, 2021 | 255,893,726 | |||||||||||
Balance at Dec. 31, 2021 | $ 171,000 | 143,718,000 | (139,121,000) | (115,000) | (3,720,000) | 933,000 | ||||||
Balance (in shares) at Mar. 31, 2021 | 239,963,788 | |||||||||||
Balance at Mar. 31, 2021 | $ 161,000 | 138,363,000 | (133,672,000) | (103,000) | (3,977,000) | 772,000 | ||||||
Sale of common stock for cash (in shares) | 8,627,237 | |||||||||||
Sale of common stock for cash | $ 6,000 | 1,408,000 | 0 | 0 | 0 | 1,414,000 | ||||||
Issuance of common stock for service (in shares) | 357,132 | |||||||||||
Issuance of common stock for service | $ 0 | 60,000 | 0 | 0 | 0 | 60,000 | ||||||
Stock option compensation expense | 0 | 102,000 | 0 | 0 | 0 | 102,000 | 0 | 330,000 | 0 | 0 | 0 | 330,000 |
Noncontrolling interest allocation | 0 | (314,000) | 0 | 0 | 314,000 | 0 | ||||||
Net loss | 0 | 0 | (1,622,000) | 0 | (168,000) | (1,790,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Foreign currency translation | $ 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Balance (in shares) at Jun. 30, 2021 | 250,996,373 | |||||||||||
Balance at Jun. 30, 2021 | $ 168,000 | 140,292,000 | (135,294,000) | (103,000) | (3,831,000) | 1,232,000 | ||||||
Conversion of notes (in shares) | 1,966,439 | |||||||||||
Conversion of notes | $ 1,000 | 327,000 | 0 | 0 | 0 | 328,000 | ||||||
Issuance of common stock for interest (in shares) | 81,777 | |||||||||||
Issuance of common stock for interest | $ 0 | 16,000 | 0 | 0 | 0 | 16,000 | ||||||
Sale of common stock for cash (in shares) | 648,805 | |||||||||||
Sale of common stock for cash | $ 1,000 | 122,000 | 0 | 0 | 0 | 123,000 | ||||||
Stock option compensation expense | 0 | 179,000 | 0 | 0 | 0 | 179,000 | 0 | 251,000 | 0 | 0 | 0 | 251,000 |
Noncontrolling interest allocation | 0 | (159,000) | 0 | 0 | 159,000 | 0 | ||||||
Net loss | 0 | 0 | (1,301,000) | 0 | (134,000) | (1,435,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | (7,000) | 0 | (7,000) | ||||||
Foreign currency translation | $ 0 | 0 | 0 | (7,000) | 0 | (7,000) | ||||||
Balance (in shares) at Sep. 30, 2021 | 255,368,553 | |||||||||||
Balance at Sep. 30, 2021 | $ 171,000 | 141,343,000 | (136,595,000) | (110,000) | (3,806,000) | 1,003,000 | ||||||
Conversion of notes (in shares) | 3,306,708 | |||||||||||
Conversion of notes | $ 2,000 | 598,000 | 0 | 0 | 0 | 600,000 | ||||||
Issuance of common stock for interest (in shares) | 416,667 | |||||||||||
Issuance of common stock for interest | $ 0 | 60,000 | 0 | 0 | 0 | 60,000 | ||||||
Balance (in shares) at Dec. 31, 2021 | 255,893,726 | |||||||||||
Balance at Dec. 31, 2021 | $ 171,000 | 143,718,000 | (139,121,000) | (115,000) | (3,720,000) | 933,000 | ||||||
Sale of common stock for cash (in shares) | 6,703,789 | |||||||||||
Sale of common stock for cash | $ 4,000 | 1,198,000 | 0 | 0 | 0 | 1,202,000 | ||||||
Issuance of common stock for service (in shares) | 86,752 | |||||||||||
Issuance of common stock for service | $ 0 | 17,000 | 0 | 0 | 0 | 17,000 | ||||||
Stock option compensation expense | 0 | 141,000 | 0 | 0 | 0 | 141,000 | 0 | 660,000 | 0 | 0 | 0 | 660,000 |
Noncontrolling interest allocation | 0 | (528,000) | 0 | 0 | 528,000 | 0 | ||||||
Net loss | 0 | 0 | (1,652,000) | 0 | 108,000 | (1,544,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | (8,000) | 0 | (8,000) | ||||||
Foreign currency translation | $ 0 | 0 | 0 | (8,000) | 0 | (8,000) | ||||||
Balance (in shares) at Mar. 31, 2022 | 262,684,267 | |||||||||||
Balance at Mar. 31, 2022 | $ 175,000 | 145,206,000 | (140,773,000) | (123,000) | (3,084,000) | 1,401,000 | ||||||
Balance (in shares) at Dec. 31, 2021 | 255,893,726 | |||||||||||
Balance at Dec. 31, 2021 | $ 171,000 | 143,718,000 | (139,121,000) | (115,000) | (3,720,000) | 933,000 | ||||||
Net loss | (3,724,000) | |||||||||||
Foreign currency translation | (70,000) | |||||||||||
Foreign currency translation | (70,000) | |||||||||||
Balance (in shares) at Sep. 30, 2022 | 274,622,640 | |||||||||||
Balance at Sep. 30, 2022 | $ 184,000 | 147,470,000 | (142,505,000) | (185,000) | (2,931,000) | 2,033,000 | ||||||
Balance (in shares) at Mar. 31, 2022 | 262,684,267 | |||||||||||
Balance at Mar. 31, 2022 | $ 175,000 | 145,206,000 | (140,773,000) | (123,000) | (3,084,000) | 1,401,000 | ||||||
Sale of common stock for cash (in shares) | 5,011,570 | |||||||||||
Sale of common stock for cash | $ 4,000 | 944,000 | 0 | 0 | 0 | 948,000 | ||||||
Issuance of common stock for service (in shares) | 340,891 | |||||||||||
Issuance of common stock for service | $ 0 | 59,000 | 0 | 0 | 0 | 59,000 | ||||||
Stock option compensation expense | 0 | 82,000 | 0 | 0 | 0 | 82,000 | 0 | 234,000 | 0 | 0 | 0 | 234,000 |
Noncontrolling interest allocation | 0 | (103,000) | 0 | 0 | 103,000 | 0 | ||||||
Net loss | 0 | 0 | (1,228,000) | 0 | (105,000) | (1,333,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | (3,000) | 0 | (3,000) | ||||||
Foreign currency translation | $ 0 | 0 | 0 | (3,000) | 0 | (3,000) | ||||||
Balance (in shares) at Jun. 30, 2022 | 268,036,728 | |||||||||||
Balance at Jun. 30, 2022 | $ 179,000 | 146,422,000 | (142,001,000) | (126,000) | (3,086,000) | 1,388,000 | ||||||
Sale of common stock for cash (in shares) | 6,207,084 | |||||||||||
Sale of common stock for cash | $ 4,000 | 1,113,000 | 0 | 0 | 0 | 1,117,000 | ||||||
Issuance of common stock for service (in shares) | 378,828 | |||||||||||
Issuance of common stock for service | $ 1,000 | 95,000 | 0 | 0 | 0 | 96,000 | ||||||
Stock option compensation expense | $ 0 | $ 85,000 | $ 0 | $ 0 | $ 0 | $ 85,000 | 0 | 253,000 | 0 | 0 | 0 | 253,000 |
Noncontrolling interest allocation | 0 | (498,000) | 0 | 0 | 498,000 | 0 | ||||||
Net loss | 0 | 0 | (504,000) | 0 | (343,000) | (847,000) | ||||||
Foreign currency translation | 0 | 0 | 0 | (59,000) | 0 | (59,000) | ||||||
Foreign currency translation | $ 0 | 0 | 0 | (59,000) | 0 | (59,000) | ||||||
Balance (in shares) at Sep. 30, 2022 | 274,622,640 | |||||||||||
Balance at Sep. 30, 2022 | $ 184,000 | $ 147,470,000 | $ (142,505,000) | $ (185,000) | $ (2,931,000) | $ 2,033,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities | ||
Net loss | $ (3,724,000) | $ (5,103,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock option compensation expense | 1,455,000 | 1,447,000 |
Common stock issued in lieu of salary to officers and fees for services from vendors | 172,000 | 294,000 |
Common stock issued for interest | 0 | 16,000 |
Interest expense related to amortization of the discount on convertible notes payable and line of credit | 13,000 | 114,000 |
PPP loan forgiveness | (174,000) | (43,000) |
Loss on investment in South Korean joint venture | 15,000 | 23,000 |
Depreciation expense | 28,000 | 17,000 |
Changes in assets and liabilities: | ||
Accounts receivable | (371,000) | 20,000 |
Prepaid expenses and other current assets | (85,000) | (71,000) |
Inventories | (19,000) | 27,000 |
Contract liability | (83,000) | 114,000 |
Customer deposits | 30,000 | 79,000 |
Net cash used in operating activities | (2,803,000) | (2,962,000) |
Cash flows from investing activities | ||
Purchase of equipment | (164,000) | (21,000) |
Net cash used in investing activities | (164,000) | (21,000) |
Cash flows from financing activities | ||
Proceeds from sales of common stock | 3,267,000 | 4,120,000 |
Exercise of warrants | 0 | 60,000 |
Payment of debt obligations | 0 | (828,000) |
Net cash provided by financing activities | 3,343,000 | 3,374,000 |
Net effect of foreign currency translation | (70,000) | (9,000) |
Net change in cash | 306,000 | 382,000 |
Cash at beginning of period | 962,000 | 716,000 |
Cash at end of period | 1,268,000 | 1,098,000 |
Supplemental disclosures of cash flow information | ||
Interest | 11,000 | 56,000 |
Non-cash investing and financing activities | ||
Fair value of warrants issued with convertible notes | 0 | 35,000 |
Conversion of notes payable to common stock | 0 | 328,000 |
Right of use | 433,000 | 0 |
Allocation of noncontrolling interest | 1,129,000 | 786,000 |
Clyra Medical Common Stock [Member] | ||
Cash flows from financing activities | ||
Proceeds from sales of common stock | 0 | 50,000 |
Proceeds from the issuance of Clyra Medical convertible notes | 100,000 | 0 |
Payment of Clyra Medical debt obligations | (24,000) | (28,000) |
Entities, Excluding Partially Owned Subsidiary [Member] | ||
Changes in assets and liabilities: | ||
Accounts payable and accrued expenses | (40,000) | (85,000) |
Accounts payable and accrued expenses | (40,000) | (85,000) |
Partially Owned Subsidiary [Member] | ||
Changes in assets and liabilities: | ||
Accounts payable and accrued expenses | (20,000) | 189,000 |
Accounts payable and accrued expenses | $ (20,000) | $ 189,000 |
Note 1 - Business and Organizat
Note 1 - Business and Organization | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. Description of Business BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air and a cleaner earth. The company also owns a majority interest in a medical products subsidiary that has licensed BioLargo’s technologies. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. For the nine September 30, 2022, September 30, 2022, three September 30, 2022, one 9. We do not December 31, 2022, March 2023, 3. If we are unable to rely on our current arrangement with Lincoln Park to continue to fund our working capital requirements, we will have to rely on other forms of financing, and there is no The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to continue to raise funds through stock sales to Lincoln Park or other private financings, and in the long term, our ability to attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technologies. The consolidated financial statements do not Organization We are a Delaware corporation formed in 1991. four 2006; 2009; 2019, 2014; 2016. 2017. 2012, 2, 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not nine September 30, 2022 not may December 31, 2022, 10 December 31, 2021, March 31, 2022. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2. In the opinion of management, the accompanying balance sheet and related statements of operations, cash flows, and stockholders’ deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of September 30, 2022 December 31, 2021, September 30, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 1,251 $ 941 Clyra Medical Technologies, Inc. 17 21 Total $ 1,268 $ 962 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of September 30, 2022 $12,000 December 31, 2021, $12,000 Credit Concentration We had a limited number of customers that account for significant portions of our revenue. During the nine September 30, 2022 2021, 10% September 30, 2022 September 30, 2021 Customer A 44 % <10 % Customer B 14 % <10 % Customer C <10 % 12 % Customer D <10 % 14 % Customer E <10 % 11 % We had a limited number of customers that accounted for more than 10% September 30, 2022, December 31, 2021, September 30, 2022 December 31, 2021 Customer A 13 % <10 % Customer B 15 % <10 % Customer F 11 % <10 % Customer G <10 % 32 % Customer H <10 % 12 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of September 30, 2022, December 31, 2021, $3,000 September 30, 2022 December 31, 2021 Raw material $ 123 $ 108 Finished goods 137 103 Total $ 260 $ 241 Other Non-Current Assets September 30, 2022 December 31, 2021 Patents $ 34 $ 34 Security deposits 35 35 Tax credit receivable 54 $ - Total $ 123 $ 69 Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not nine September 30, 2022 2021, $23,000, Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not nine September 30, 2022 2021, Nevertheless, during the three December 31, 2021, 2021 $342,000. Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2022 2021, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the nine September 30, 2022 2021: 2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 – 3.83% 2.32 – 3.83% 1.73 % 0.93 – 1.73% Expected volatility 115 – 117% 115 – 117% 124 % 121 – 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered, or product is received. Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We generate revenue through our subsidiaries. For the sale of goods, the subsidiary identifies its contract with the customer through a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product and each product has separate pricing. Revenue is recognized at a point in time when the order for its goods are shipped if its agreement with the customer is FOB manufacturer, and when goods are delivered to its customer if its agreement with the customer is FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. In association with certain product purchases, ONM Environmental installs misting systems for which it bills on a time and materials basis. It identifies its contract with the customer through a written purchase order in which the details of the time to be billed and materials purchased and an estimated completion date. The performance obligation is the completion of the installation, and at that time revenue is recognized. For services, such as through our engineering group, the subsidiary identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. Service contracts typically call for invoicing for time and materials incurred for that contract, although some provide for milestone or fixed cost payments, where an agreed-to amount is invoiced per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a contract receivable or contract liability is created. As of September 30, 2022, December 31, 2021, Royalties or license fees from our intellectual property are based on the licensee’s sales of products incorporating or using our licensed intellectual property. Government Grants We have been awarded multiple research grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 third third nine eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no September 30, 2022, December 31, 2021. The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not September 30, 2022. The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of September 30, 2022 December 31, 2021, Tax Credits Our research and development activities in Canada may not Leases In February 2016, No. 2016 02, 10 January 1, 2019 July 2018, may 842, No September 30, 2022, Recent Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 1 not not 2 December 15, 2021, December 15, 2023, January 1, 2022. three June 30, 2022 ( 8 not 815 15. no |
Note 3 - Sale of Stock for Cash
Note 3 - Sale of Stock for Cash | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Stock Purchase Agreement [Text Block] | Note 3. Lincoln Park Financing During the three nine September 30, 2022, During the three nine September 30, 2021, Unit Offerings During the three nine September 30, 2022, thirty During the three nine September 30, 2021, four In addition to the shares, we issued each investor a six five 6, |
Note 4 - Debt Obligations
Note 4 - Debt Obligations | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 4. The following table summarizes our debt obligations outstanding as of September 30, 2022, December 31, 2021 ( not 8, September 30, 2022 (Unaudited) December 31, 2021 Current portion of debt: SBA Paycheck Protection Program loans, mature April 2025 $ 43 $ 314 Convertible note payable, matures March 1, 2023 50 — Debt discount, net of amortization (7 ) — Total current portion of debt $ 86 $ 314 Long-term debt: SBA EIDL Loan $ 150 $ 150 SBA Paycheck Protection Program loans, mature May 2025 97 — Convertible note payable, matures March 1, 2023 — 50 Debt discount, net of amortization — (20 ) Total long-term debt 247 180 Total $ 333 $ 494 For the three nine September 30, 2022, three nine September 30, 2021, The following discussion includes debt instruments to which amendments were made or included other activity that management deemed appropriate to disclose during the nine September 30, 2022 2021. 10 March 31, 2022. SBA Program Loans In April 2020, two 1%. February 7, 2022, $174,000; March 19, 2021, |
Note 5 - Share-based Compensati
Note 5 - Share-based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 5. Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries On September 30, 2022, On September 30, 2021, March 31, 2021, Payment of Consultant Fees On September 30, 2022, June 30, 2022, March 31, 2022, On September 30, 2021, June 30, 2021, March 31, 2021, Payment of Accrued Interest During the three June 30, 2021, Stock Option Expense During the three nine September 30, 2022, three nine September 30, 2021, 2018 2007 8 2018 On June 22, 2018, 2018 “2018 may 2018 2018 January 1st Activity for our stock options under the 2018 nine September 30, 2022 September 30, 2021, Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding Price per share share Value (1) Balance, December 31, 2021 23,186,142 $0.12 – 0.43 $ 0.19 Granted 4,748,212 0.18 – 0.27 0.22 Balance, September 30, 2022 27,934,354 $0.12 – 0.43 $ 0.19 Non-vested (4,449,874 ) 0.12 – 0.40 0.22 Vested, September 30, 2022 23,484,480 $0.12 – 0.43 $ 0.19 $ 1,893,000 Balance, December 31, 2020 18,865,525 $0.16 – 0.40 $ 0.19 Granted 3,686,462 0.13 – 0.23 0.19 Balance, September 30, 2021 22,591,987 $0.12 – 0.43 $ 0.19 ( 1 September 30, 2022. The options granted to purchase 4,748,212 shares during the nine September 30, 2022 $246,000; four Chief Financial Officer Contract Extension On March 22, 2022, February 1, 2008 ( March 22, 2022 ( one January 31, 2023 ( As the sole compensation for the Extended Term, Mr. Dargan was issued an option (“Option”) to purchase 25,000 shares of the Company’s common stock for each month during the Extended Term (thus, an option to purchase 300,000 12 March 22, 2022, March 22, 2022, March 22, 2022, ten 2018 The Option is Mr. Dargan’s sole compensation for the Extended Term. As was the case in all prior terms of his engagement, there is no no not The options granted to purchase 3,686,462 shares during the nine September 30, 2021 $198,000; four 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may September 7, 2017. September 2017, Activity for our stock options under the 2007 nine September 30, 2022 2021 Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding price per share share Value (1) Balance, December 31, 2021 2,879,246 $0.28 – 0.94 $ 0.49 Expired (975,161 ) $0.28 – 0.35 0.36 Balance, September 30, 2022 1,904,085 $0.28 – 0.94 $ 0.56 $ — Balance, December 31, 2020 5,689,363 $0.28 – 0.94 $ 0.44 Expired (1,769,008 ) 0.39 – 0.51 0.40 Balance, September 30, 2021 3,920,355 $0.28 – 1.65 $ 0.45 ( 1 September 30, 2022. Non-Plan Options issued Activity of our non-plan stock options issued for the nine September 30, 2022 2021 Weighted Non-plan average Aggregate Options Exercise price per Intrinsic Outstanding price per share share value (1) Balance, December 31, 2021 20,119,207 $0.17 – 1.00 $ 0.41 Granted 105,797 $0.23 – 0.27 0.26 Balance, September 30, 2022 20,225,004 $0.17 – 1.00 $ 0.39 Non-vested (1,050,000 ) 0.17 – 0.45 0.45 Vested, September 30, 2022 19,175,004 $0.17 – 1.00 $ 0.38 $ 274,000 Balance, December 31, 2020 20,749,583 $0.17 – 1.00 $ 0.41 Granted 43,956 0.23 0.23 Expired (800,000 ) 1.00 1.00 Balance, September 30, 2021 19,993,539 $0.17 – 1.00 $ 0.39 ( 1 September 30, 2022. During the nine September 30, 2022, $0.23 During the nine September 30, 2021, |
Note 6 - Warrants
Note 6 - Warrants | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Warrants [Text Block] | Note 6. We issued warrants to purchase our common stock, at various prices for the nine September 30, 2022 2021, Weighted average Aggregate Warrants Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 36,765,502 $0.16 – 1.00 $ 0.27 Issued 27,137,048 0.19 – 0.33 0.23 Expired (10,273,722 ) 0.19 – 0.48 0.25 Balance, September 30, 2022 53,628,828 $0.14 – 1.00 $ 0.26 $ 2,094,000 Balance, December 31, 2020 32,980,989 $0.16 – 1.00 $ 0.29 Issued 7,865,872 0.14 - 0.27 0.20 Exercised (416,667 ) 0.14 0.14 Expired (2,743,406 ) 0.12 - 0.70 0.59 Balance, September 30, 2021 37,686,788 $0.12 – 1.00 $ 0.27 ( 1 Aggregate intrinsic value based on closing common stock price of $0.27 at September 30, 2022 Warrants issued in Unit Offerings During the nine September 30, 2022, 3 nine five During the nine September 30, 2021, 3 six five On August 6, 2021 six Fair Value – Interest Expense To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement, management also uses the option-pricing model. During the nine September 30, 2022 2021, no The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant. |
Note 7 - Accounts Payable and A
Note 7 - Accounts Payable and Accrued Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 7. Accounts payable and accrued expenses for our operations other than our partially-owned subsidiary Clyra Medical included the following (in thousands): September 30, 2022 December 31, 2021 Accounts payable and accrued expense $ 334 $ 349 Accrued interest 25 25 Accrued payroll 161 185 Total accounts payable and accrued expenses $ 520 $ 559 Accounts payable and accrued expenses includes ordinary business payables incurred by the Company and its operational subsidiaries. See Note 8, |
Note 8 - Noncontrolling Interes
Note 8 - Noncontrolling Interest - Clyra Medical | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 8. Clyra Medical We consolidate the operations of our partially owned subsidiary Clyra Medical, of which we owned 58% of its outstanding shares as of September 30, 2022. BioLargo and its partially owned subsidiary Clyra Medical entered into an agreement dated March 3, 2022, Debt Obligations of Clyra Medical On April 8, 2022, April 8, 2024 may On June 30, 2020, September 30, 2022, one Prepaid Marketing - Consulting Agreement On December 30, 2015, four June 30, 2020, three not 2021, Clyra Medical Equity transactions As of September 30, 2022, Shareholder Shares Percent BioLargo, Inc. 51,249 58 % Sanatio Capital 18,704 21 % Other 19,118 21 % Total 89,071 Sales of Common Shares During the nine September 30, 2022 2021, Stock Options Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. As of December 31, 2021, nine September 30, 2022 2021, nine September 30, 2022 2021 no Clyra Accounts Payable and Accrued Expenses Clyra had the following accounts payable and accrued expenses as follows: September 30, 2022 December 31, 2021 Accounts payable and accrued expense $ 202 $ 149 Accrued interest 4 51 Accrued payroll 5 30 Total Clyra Medical accounts payable and accrued expenses $ 211,000 $ 230 |
Note 9 - Business Segment Infor
Note 9 - Business Segment Information | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | Note 9. BioLargo currently has four operating business segments, plus its corporate entity which is responsible for general corporate operations, including administrative functions, finance, human resources, marketing, legal, etc. The four ONM Environmental (“ONM”) -- which sells odor and volatile organic control products and services (located in Westminster, California); 1. ONM Environmental (“ONM”) -- which sells odor and volatile organic control products and services (located in Westminster, California); 2. Clyra Medical Technologies (“Clyra”) -- which develops and sells medical products based on our technologies, including BioClynse wound irrigation solution; 3. BLEST -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed (located in Oak Ridge, Tennessee); and 4. BioLargo Water (“Water”) -- which historically focused entirely on R&D, and has now shifted its focus to commercializing the AOS technology (located in Edmonton, Alberta Canada). Historically, none third The segment information for the three nine September 30, 2022 2021, Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Revenue BioLargo corporate $ 2 $ — $ 4 $ 7 ONM 1,199 420 2,499 1,058 BLEST 401 416 1,613 1,070 Water 1 2 1 9 Clyra Medical 17 9 34 114 Intersegment revenue (120 ) (135 ) (365 ) (522 ) Total $ 1,500 $ 712 $ 3,786 $ 1,743 Operating income (loss) BioLargo corporate $ (783 ) $ (868 ) $ (2,925 ) $ (2,726 ) ONM 400 (72 ) 418 (355 ) Clyra Medical (240 ) (219 ) (736 ) (958 ) BLEST (179 ) (140 ) (158 ) (513 ) Water (141 ) (156 ) (572 ) (461 ) Total $ (943 ) $ (1,455 ) $ (3,973 ) $ (5,013 ) Interest expense BioLargo corporate $ (6 ) $ (6 ) $ (18 ) $ (106 ) Clyra Medical (8 ) (20 ) (24 ) (96 ) Total $ (14 ) $ (26 ) $ (42 ) $ (208 ) Research and development expense BioLargo corporate $ (140 ) $ (220 ) $ (570 ) $ (765 ) Clyra Medical (31 ) (20 ) (73 ) (53 ) BLEST (100 ) (123 ) (288 ) (358 ) Water (119 ) (109 ) (446 ) (366 ) Intersegment R&D 119 135 359 515 Total $ (271 ) $ (344 ) $ (1,018 ) $ (1,027 ) The segment asset information for September 30, 2022 December 31, 2021, As September 30, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 785 $ 1,079 $ 814 $ 590 $ 194 $ (20 ) $ 3,442 Right of use 157 — — 739 — — 896 Investment in South Korean joint venture 33 — — — — — 33 Total 975 1,079 814 1,329 194 (20 ) 4,371 As of December 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 690 $ 451 $ 832 $ 445 $ 152 $ (47 ) $ 2,522 Right of use 222 — — 231 — — 453 Investment in South Korean joint venture 48 — — — — — 48 Total 960 451 832 676 152 (47 ) 3,023 |
Note 10 - Commitments and Conti
Note 10 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 10. Office Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. For the nine September 30, 2022 2021, September 30, 2022, nine We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. On January 1, 2019, 842 not August 2024. four four not September 2022, ten ten September 30, 2022 one None no not no |
Note 11 - Subsequent Events
Note 11 - Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 11. Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure. Sales to Lincoln Park From October 1, 2022, November 10, 2022, 3 Unit Offering Investments From October 1, 2022, November 10, 2022, fifteen 3 six five |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of September 30, 2022 December 31, 2021, September 30, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 1,251 $ 941 Clyra Medical Technologies, Inc. 17 21 Total $ 1,268 $ 962 |
Receivable [Policy Text Block] | Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of September 30, 2022 $12,000 December 31, 2021, $12,000 |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Credit Concentration We had a limited number of customers that account for significant portions of our revenue. During the nine September 30, 2022 2021, 10% September 30, 2022 September 30, 2021 Customer A 44 % <10 % Customer B 14 % <10 % Customer C <10 % 12 % Customer D <10 % 14 % Customer E <10 % 11 % We had a limited number of customers that accounted for more than 10% September 30, 2022, December 31, 2021, September 30, 2022 December 31, 2021 Customer A 13 % <10 % Customer B 15 % <10 % Customer F 11 % <10 % Customer G <10 % 32 % Customer H <10 % 12 % |
Inventory, Policy [Policy Text Block] | Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of September 30, 2022, December 31, 2021, $3,000 September 30, 2022 December 31, 2021 Raw material $ 123 $ 108 Finished goods 137 103 Total $ 260 $ 241 |
Other Assets, Policy [Policy Text Block] | Other Non-Current Assets September 30, 2022 December 31, 2021 Patents $ 34 $ 34 Security deposits 35 35 Tax credit receivable 54 $ - Total $ 123 $ 69 |
Equity Method Investments [Policy Text Block] | Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not nine September 30, 2022 2021, $23,000, |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not nine September 30, 2022 2021, Nevertheless, during the three December 31, 2021, 2021 $342,000. |
Earnings Per Share, Policy [Policy Text Block] | Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2022 2021, |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. |
Share-Based Payment Arrangement [Policy Text Block] | Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the nine September 30, 2022 2021: 2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 – 3.83% 2.32 – 3.83% 1.73 % 0.93 – 1.73% Expected volatility 115 – 117% 115 – 117% 124 % 121 – 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not |
Warrant Policy [Policy Text Block] | Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. |
Non Cash Transactions [Policy Text Block] | Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered, or product is received. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We generate revenue through our subsidiaries. For the sale of goods, the subsidiary identifies its contract with the customer through a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product and each product has separate pricing. Revenue is recognized at a point in time when the order for its goods are shipped if its agreement with the customer is FOB manufacturer, and when goods are delivered to its customer if its agreement with the customer is FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. In association with certain product purchases, ONM Environmental installs misting systems for which it bills on a time and materials basis. It identifies its contract with the customer through a written purchase order in which the details of the time to be billed and materials purchased and an estimated completion date. The performance obligation is the completion of the installation, and at that time revenue is recognized. For services, such as through our engineering group, the subsidiary identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. Service contracts typically call for invoicing for time and materials incurred for that contract, although some provide for milestone or fixed cost payments, where an agreed-to amount is invoiced per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a contract receivable or contract liability is created. As of September 30, 2022, December 31, 2021, Royalties or license fees from our intellectual property are based on the licensee’s sales of products incorporating or using our licensed intellectual property. |
Government Grants [Policy Text Block] | Government Grants We have been awarded multiple research grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 third third nine eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no |
Income Tax, Policy [Policy Text Block] | Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no September 30, 2022, December 31, 2021. The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not September 30, 2022. The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of September 30, 2022 December 31, 2021, |
Tax Credits [Policy Text Block] | Tax Credits Our research and development activities in Canada may not |
Lessee, Leases [Policy Text Block] | Leases In February 2016, No. 2016 02, 10 January 1, 2019 July 2018, may 842, No September 30, 2022, |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 1 not not 2 December 15, 2021, December 15, 2023, January 1, 2022. three June 30, 2022 ( 8 not 815 15. no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Cash and Cash Equivalents [Table Text Block] | September 30, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 1,251 $ 941 Clyra Medical Technologies, Inc. 17 21 Total $ 1,268 $ 962 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | September 30, 2022 September 30, 2021 Customer A 44 % <10 % Customer B 14 % <10 % Customer C <10 % 12 % Customer D <10 % 14 % Customer E <10 % 11 % September 30, 2022 December 31, 2021 Customer A 13 % <10 % Customer B 15 % <10 % Customer F 11 % <10 % Customer G <10 % 32 % Customer H <10 % 12 % |
Schedule of Inventory, Current [Table Text Block] | September 30, 2022 December 31, 2021 Raw material $ 123 $ 108 Finished goods 137 103 Total $ 260 $ 241 |
Schedule of Other Assets, Noncurrent [Table Text Block] | September 30, 2022 December 31, 2021 Patents $ 34 $ 34 Security deposits 35 35 Tax credit receivable 54 $ - Total $ 123 $ 69 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 – 3.83% 2.32 – 3.83% 1.73 % 0.93 – 1.73% Expected volatility 115 – 117% 115 – 117% 124 % 121 – 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 |
Note 4 - Debt Obligations (Tabl
Note 4 - Debt Obligations (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | September 30, 2022 (Unaudited) December 31, 2021 Current portion of debt: SBA Paycheck Protection Program loans, mature April 2025 $ 43 $ 314 Convertible note payable, matures March 1, 2023 50 — Debt discount, net of amortization (7 ) — Total current portion of debt $ 86 $ 314 Long-term debt: SBA EIDL Loan $ 150 $ 150 SBA Paycheck Protection Program loans, mature May 2025 97 — Convertible note payable, matures March 1, 2023 — 50 Debt discount, net of amortization — (20 ) Total long-term debt 247 180 Total $ 333 $ 494 |
Note 5 - Share-based Compensa_2
Note 5 - Share-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding Price per share share Value (1) Balance, December 31, 2021 23,186,142 $0.12 – 0.43 $ 0.19 Granted 4,748,212 0.18 – 0.27 0.22 Balance, September 30, 2022 27,934,354 $0.12 – 0.43 $ 0.19 Non-vested (4,449,874 ) 0.12 – 0.40 0.22 Vested, September 30, 2022 23,484,480 $0.12 – 0.43 $ 0.19 $ 1,893,000 Balance, December 31, 2020 18,865,525 $0.16 – 0.40 $ 0.19 Granted 3,686,462 0.13 – 0.23 0.19 Balance, September 30, 2021 22,591,987 $0.12 – 0.43 $ 0.19 Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding price per share share Value (1) Balance, December 31, 2021 2,879,246 $0.28 – 0.94 $ 0.49 Expired (975,161 ) $0.28 – 0.35 0.36 Balance, September 30, 2022 1,904,085 $0.28 – 0.94 $ 0.56 $ — Balance, December 31, 2020 5,689,363 $0.28 – 0.94 $ 0.44 Expired (1,769,008 ) 0.39 – 0.51 0.40 Balance, September 30, 2021 3,920,355 $0.28 – 1.65 $ 0.45 Weighted Non-plan average Aggregate Options Exercise price per Intrinsic Outstanding price per share share value (1) Balance, December 31, 2021 20,119,207 $0.17 – 1.00 $ 0.41 Granted 105,797 $0.23 – 0.27 0.26 Balance, September 30, 2022 20,225,004 $0.17 – 1.00 $ 0.39 Non-vested (1,050,000 ) 0.17 – 0.45 0.45 Vested, September 30, 2022 19,175,004 $0.17 – 1.00 $ 0.38 $ 274,000 Balance, December 31, 2020 20,749,583 $0.17 – 1.00 $ 0.41 Granted 43,956 0.23 0.23 Expired (800,000 ) 1.00 1.00 Balance, September 30, 2021 19,993,539 $0.17 – 1.00 $ 0.39 |
Note 6 - Warrants (Tables)
Note 6 - Warrants (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Weighted average Aggregate Warrants Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 36,765,502 $0.16 – 1.00 $ 0.27 Issued 27,137,048 0.19 – 0.33 0.23 Expired (10,273,722 ) 0.19 – 0.48 0.25 Balance, September 30, 2022 53,628,828 $0.14 – 1.00 $ 0.26 $ 2,094,000 Balance, December 31, 2020 32,980,989 $0.16 – 1.00 $ 0.29 Issued 7,865,872 0.14 - 0.27 0.20 Exercised (416,667 ) 0.14 0.14 Expired (2,743,406 ) 0.12 - 0.70 0.59 Balance, September 30, 2021 37,686,788 $0.12 – 1.00 $ 0.27 |
Note 7 - Accounts Payable and_2
Note 7 - Accounts Payable and Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | September 30, 2022 December 31, 2021 Accounts payable and accrued expense $ 334 $ 349 Accrued interest 25 25 Accrued payroll 161 185 Total accounts payable and accrued expenses $ 520 $ 559 |
Note 8 - Noncontrolling Inter_2
Note 8 - Noncontrolling Interest - Clyra Medical (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Other Ownership Interests [Table Text Block] | Shareholder Shares Percent BioLargo, Inc. 51,249 58 % Sanatio Capital 18,704 21 % Other 19,118 21 % Total 89,071 |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | September 30, 2022 December 31, 2021 Accounts payable and accrued expense $ 334 $ 349 Accrued interest 25 25 Accrued payroll 161 185 Total accounts payable and accrued expenses $ 520 $ 559 |
Clyra Medical [Member] | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | September 30, 2022 December 31, 2021 Accounts payable and accrued expense $ 202 $ 149 Accrued interest 4 51 Accrued payroll 5 30 Total Clyra Medical accounts payable and accrued expenses $ 211,000 $ 230 |
Note 9 - Business Segment Inf_2
Note 9 - Business Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Revenue BioLargo corporate $ 2 $ — $ 4 $ 7 ONM 1,199 420 2,499 1,058 BLEST 401 416 1,613 1,070 Water 1 2 1 9 Clyra Medical 17 9 34 114 Intersegment revenue (120 ) (135 ) (365 ) (522 ) Total $ 1,500 $ 712 $ 3,786 $ 1,743 Operating income (loss) BioLargo corporate $ (783 ) $ (868 ) $ (2,925 ) $ (2,726 ) ONM 400 (72 ) 418 (355 ) Clyra Medical (240 ) (219 ) (736 ) (958 ) BLEST (179 ) (140 ) (158 ) (513 ) Water (141 ) (156 ) (572 ) (461 ) Total $ (943 ) $ (1,455 ) $ (3,973 ) $ (5,013 ) Interest expense BioLargo corporate $ (6 ) $ (6 ) $ (18 ) $ (106 ) Clyra Medical (8 ) (20 ) (24 ) (96 ) Total $ (14 ) $ (26 ) $ (42 ) $ (208 ) Research and development expense BioLargo corporate $ (140 ) $ (220 ) $ (570 ) $ (765 ) Clyra Medical (31 ) (20 ) (73 ) (53 ) BLEST (100 ) (123 ) (288 ) (358 ) Water (119 ) (109 ) (446 ) (366 ) Intersegment R&D 119 135 359 515 Total $ (271 ) $ (344 ) $ (1,018 ) $ (1,027 ) As September 30, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 785 $ 1,079 $ 814 $ 590 $ 194 $ (20 ) $ 3,442 Right of use 157 — — 739 — — 896 Investment in South Korean joint venture 33 — — — — — 33 Total 975 1,079 814 1,329 194 (20 ) 4,371 As of December 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 690 $ 451 $ 832 $ 445 $ 152 $ (47 ) $ 2,522 Right of use 222 — — 231 — — 453 Investment in South Korean joint venture 48 — — — — — 48 Total 960 451 832 676 152 (47 ) 3,023 |
Note 1 - Business and Organiz_2
Note 1 - Business and Organization (Details Textual) | 3 Months Ended | 9 Months Ended | |||||||
Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | $ (847,000) | $ (1,333,000) | $ (1,544,000) | $ (1,435,000) | $ (1,790,000) | $ (1,878,000) | $ (3,724,000) | $ (5,103,000) | |
Net Cash Provided by (Used in) Operating Activities, Total | (2,803,000) | (2,962,000) | |||||||
Working Capital (Deficit) | 1,503,000 | 1,503,000 | |||||||
Assets, Current, Total | 2,532,000 | 2,532,000 | $ 1,801,000 | ||||||
Revenue from Contract with Customer, Including Assessed Tax | $ 1,500,000 | $ 712,000 | $ 3,786,000 | $ 1,743,000 | |||||
Number of Wholly-Owned Subsidiaries | 4 | 4 | |||||||
BioLargo Engineering, Science & Technologies, LLC [Member] | |||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 89% | 89% | |||||||
Clyra Medical Technologies [Member] | |||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 58% | 58% |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | 9 Months Ended | ||||
Mar. 20, 2020 | Jan. 01, 2019 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Accounts Receivable, Allowance for Credit Loss, Current | $ 12,000 | $ 12,000 | |||
Inventory Valuation Reserves, Ending Balance | 3,000 | 3,000 | |||
Income (Loss) from Equity Method Investments | (15,000) | $ (23,000) | |||
Impairment, Long-Lived Asset, Held-for-Use, Total | 0 | $ 0 | |||
Contract with Customer, Liability, Total | 6,000 | 89,000 | |||
Contract with Customer, Refund Liability, Total | 0 | ||||
Unrecognized Tax Benefits, Ending Balance | 0 | 0 | |||
Operating Lease, Right-of-Use Asset | $ 896,000 | $ 453,000 | |||
Accounting Standards Update 2016-02 [Member] | |||||
Increase (Decrease) in Operating Lease, Right-of-use Assets | $ 399,000 | ||||
Canadian Government Grants [Member] | |||||
Number of Grants Received | 80 | ||||
Grants Receivable | $ 3,700,000 | ||||
Canadian Government Grants [Member] | Other Income [Member] | |||||
Proceeds from Income Tax Refunds | $ 54,000 | ||||
Canadian Government Grants [Member] | Minimum [Member] | |||||
Grant Term (Year) | 9 years | ||||
Canadian Government Grants [Member] | Maximum [Member] | |||||
Grant Term (Year) | 18 months | ||||
Odin Co Ltd [Member] | |||||
Payments to Acquire Interest in Joint Venture | $ 100,000 | ||||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 40% | 40% | 40% | ||
Income (Loss) from Equity Method Investments | $ 15,000 | $ 23,000 | |||
Odin Co Ltd [Member] | Tomorrow Water [Member] | |||||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 30% | ||||
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member] | |||||
Payments to Acquire Interest in Joint Venture | $ 150,000 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Cash and Cash Equivalents | $ 1,268 | $ 962 |
Parent Company [Member] | ||
Cash and Cash Equivalents | 1,251 | 941 |
Noncontrolling Interest [Member] | ||
Cash and Cash Equivalents | $ 17 | $ 21 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member] | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 44% | 10% | |
Customer A [Member] | Accounts Receivable [Member] | |||
Credit concentration | 13% | 10% | |
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 14% | 10% | |
Customer B [Member] | Accounts Receivable [Member] | |||
Credit concentration | 15% | 10% | |
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 10% | 12% | |
Customer F [Member] | Accounts Receivable [Member] | |||
Credit concentration | 11% | 10% | |
Customer D [Member] | Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 10% | 14% | |
Customer G [Member] | Accounts Receivable [Member] | |||
Credit concentration | 10% | 32% | |
Customer E [Member] | Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 10% | 11% | |
Customer H [Member] | Accounts Receivable [Member] | |||
Credit concentration | 10% | 12% |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Raw material | $ 123 | $ 108 |
Finished goods | 137 | 103 |
Total | $ 260 | $ 241 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Other Non-current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Patents | $ 34 | $ 34 |
Security deposits | 35 | 35 |
Tax credit receivable | 54 | 0 |
Total | $ 123 | $ 69 |
Note 2 - Summary of Significa_8
Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Non Plan [Member] | ||
Risk free interest rate | 1.73% | |
Expected volatility | 124% | |
Expected dividend yield | 0% | 0% |
Forfeiture rate | 0% | 0% |
Life in years (Year) | 10 years | 10 years |
Non Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 2.32% | |
Expected volatility | 115% | |
Non Plan [Member] | Maximum [Member] | ||
Risk free interest rate | 3.83% | |
Expected volatility | 117% | |
2018 Equity Incentive Plan [Member] | ||
Expected dividend yield | 0% | 0% |
Forfeiture rate | 0% | 0% |
Life in years (Year) | 10 years | 10 years |
2018 Equity Incentive Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 2.32% | 0.93% |
Expected volatility | 115% | 121% |
2018 Equity Incentive Plan [Member] | Maximum [Member] | ||
Risk free interest rate | 3.83% | 1.73% |
Expected volatility | 117% | 124% |
Note 3 - Sale of Stock for Ca_2
Note 3 - Sale of Stock for Cash (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Proceeds from Issuance of Common Stock | $ 3,267,000 | $ 4,120,000 | ||
Warrants Issued with 2020 Unit Offering [Member] | Maximum [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||
The 2020 Unit Offering [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,766,126 | 388,889 | 13,568,524 | 3,820,436 |
Proceeds from Issuance of Common Stock | $ 632,000 | $ 70,000 | $ 2,364,000 | $ 575,000 |
Lincoln Park Capital Fund, LLC [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,440,958 | 2,917,819 | 4,353,919 | 21,444,128 |
Proceeds from Issuance of Common Stock | $ 485,000 | $ 530,000 | $ 903,000 | $ 3,545,000 |
Note 4 - Debt Obligations (Deta
Note 4 - Debt Obligations (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Feb. 07, 2022 | Apr. 30, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Interest Expense, Debt, Total | $ 14,000 | $ 42,000 | $ 42,000 | $ 208,000 | ||
Paycheck Protection Program CARES Act [Member] | ONM [Member] | ||||||
Proceeds from Issuance of Debt | $ 218,000 | |||||
Extinguishment of Debt, Amount | $ 174,000 | |||||
Long-Term Debt, Total | $ 43,000 | |||||
Paycheck Protection Program CARES Act [Member] | BLEST [Member] | ||||||
Proceeds from Issuance of Debt | 96,000 | |||||
Paycheck Protection Program CARES Act [Member] | Clyra Medical [Member] | ||||||
Proceeds from Issuance of Debt | $ 43,000 |
Note 4 - Debt Obligations - Sch
Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Debt discount, net of amortization | $ (7) | $ 0 |
Total current portion of debt | 86 | 314 |
Long-term debt, noncurrent | 247 | 180 |
Long-term debt | 247 | 180 |
Debt discount, net of amortization | 0 | (20) |
Total | 333 | 494 |
Paycheck Protection Program CARES Act [Member] | ||
Notes payable | 43 | 314 |
Long-term debt, noncurrent | 97 | 0 |
Long-term debt | 97 | 0 |
Convertible Note, Maturing On March 1, 2023 [Member] | ||
Convertible notes | 50 | 0 |
Long-term debt, noncurrent | 0 | 50 |
Long-term debt | 0 | 50 |
Economic Injury Disaster Loan [Member] | ||
Long-term debt, noncurrent | 150 | 150 |
Long-term debt | $ 150 | $ 150 |
Note 5 - Share-based Compensa_3
Note 5 - Share-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||||||||||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Mar. 22, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 22, 2018 | Sep. 07, 2017 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Stock Issued During Period, Value, Issued for Services | $ 96,000 | $ 59,000 | $ 17,000 | $ 60,000 | $ 111,000 | ||||||||||||
Stock Issued During Period, Value, New Issues | 1,117,000 | $ 948,000 | $ 1,202,000 | $ 123,000 | $ 1,414,000 | $ 2,106,000 | |||||||||||
Share-Based Payment Arrangement, Expense | $ 338,000 | $ 430,000 | $ 1,455,000 | $ 1,447,000 | |||||||||||||
Share Price (in dollars per share) | $ 0.27 | $ 0.27 | $ 0.27 | ||||||||||||||
2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 40,000,000 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares) | 2,000,000 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 4,748,212 | 3,686,462 | |||||||||||||||
The 2007 Equity Incentive Plan [Member] | |||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||||
Non Plan [Member] | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 105,797 | 43,956 | |||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.26 | $ 0.23 | |||||||||||||||
Common Stock Issued for Accrued Interest Due on Promissory Note [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.17 | $ 0.17 | |||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 81,777 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 16,000 | ||||||||||||||||
Officer [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 167,781 | 61,842 | 137,364 | ||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.27 | $ 0.19 | $ 0.23 | 0.27 | $ 0.19 | $ 0.23 | 0.27 | 0.19 | |||||||||
Stock Issued During Period, Value, Issued for Services | $ 72,000 | $ 12,000 | $ 31,000 | ||||||||||||||
Consultants [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 211,047 | 76,996 | 86,752 | 586,963 | 357,132 | 610,123 | |||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.27 | $ 0.18 | $ 0.23 | $ 0.19 | $ 0.17 | $ 0.23 | 0.27 | $ 0.18 | $ 0.23 | 0.19 | $ 0.17 | $ 0.23 | $ 0.27 | $ 0.19 | |||
Stock Issued During Period, Value, Issued for Services | $ 24,000 | $ 60,000 | $ 31,000 | $ 71,000 | $ 60,000 | $ 81,000 | |||||||||||
Employees, Consultants, Officers, and Directors [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 4,748,212 | 3,686,462 | |||||||||||||||
CFO and President [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 290,135 | ||||||||||||||||
CFO and President [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.22 | ||||||||||||||||
CFO and President [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.23 | ||||||||||||||||
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-Based Payment Arrangement, Expense | $ 246,000 | $ 198,000 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,134,356 | 1,049,024 | |||||||||||||||
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.18 | $ 0.17 | |||||||||||||||
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.27 | $ 0.23 | |||||||||||||||
Employees [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-Based Payment Arrangement, Expense | $ 492,000 | $ 327,000 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 2,340,730 | 1,800,011 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | 4 years | |||||||||||||||
Employees [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.18 | $ 0.17 | |||||||||||||||
Employees [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member] | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.27 | $ 0.23 | |||||||||||||||
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 145,000 | $ 95,000 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 682,991 | 537,427 | |||||||||||||||
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 300,000 | ||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.24 | $ 0.17 | |||||||||||||||
Term Extension (Year) | 1 year | ||||||||||||||||
Share-based Compensation Arrangement By Share-based Payment Award, Options Grants Per Month, Gross (in shares) | 25,000 | ||||||||||||||||
Vendors [Member] | Non Plan [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.23 | $ 0.23 | $ 0.23 | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 36,000 | $ 10,000 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 105,797 | 43,956 | |||||||||||||||
Vendors [Member] | Non Plan [Member] | Minimum [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.23 | 0.23 | $ 0.23 | ||||||||||||||
Vendors [Member] | Non Plan [Member] | Maximum [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.27 | $ 0.27 | $ 0.27 |
Note 5 - Share-based Compensa_4
Note 5 - Share-based Compensation - Stock Options (Details) - USD ($) | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | ||
2018 Equity Incentive Plan [Member] | |||
Options outstanding, balance (in shares) | 23,186,142 | 18,865,525 | |
Exercise price per share, balance (in dollars per share) | $ 0.43 | $ 0.40 | |
Options granted (in shares) | 4,748,212 | 3,686,462 | |
Exercise price per share, granted (in dollars per share) | $ 0.27 | $ 0.23 | |
Options outstanding, balance (in shares) | 27,934,354 | 22,591,987 | |
Exercise price per share, balance (in dollars per share) | $ 0.43 | $ 0.43 | |
Options Non-vested (in shares) | (4,449,874) | ||
Exercise price per share, Non-vested (in dollars per share) | $ 0.40 | ||
Options Vested (in shares) | 23,484,480 | ||
Exercise price per share, Vested (in dollars per share) | $ 0.43 | ||
Vested, September 30, 2022 (in dollars per share) | [1] | 1,893,000 | |
2018 Equity Incentive Plan [Member] | Minimum [Member] | |||
Exercise price per share, balance (in dollars per share) | 0.12 | 0.16 | |
Exercise price per share, granted (in dollars per share) | 0.18 | 0.13 | |
Exercise price per share, balance (in dollars per share) | 0.12 | 0.12 | |
Exercise price per share, Non-vested (in dollars per share) | 0.12 | ||
Exercise price per share, Vested (in dollars per share) | 0.12 | ||
2018 Equity Incentive Plan [Member] | Maximum [Member] | |||
Exercise price per share, balance (in dollars per share) | 0.19 | 0.19 | |
Exercise price per share, granted (in dollars per share) | 0.22 | 0.19 | |
Exercise price per share, balance (in dollars per share) | 0.19 | $ 0.19 | |
Exercise price per share, Non-vested (in dollars per share) | 0.22 | ||
Exercise price per share, Vested (in dollars per share) | $ 0.19 | ||
The 2007 Equity Incentive Plan [Member] | |||
Options outstanding, balance (in shares) | 2,879,246 | 5,689,363 | |
Options outstanding, balance (in shares) | 1,904,085 | 3,920,355 | |
Weighted average exercise price per share, balance (in dollars per share) | $ 0.49 | $ 0.44 | |
Options outstanding, Expired (in shares) | (975,161) | (1,769,008) | |
Weighted average exercise price per share, Expired (in dollars per share) | $ 0.36 | $ 0.40 | |
Weighted average exercise price per share, balance (in dollars per share) | 0.56 | 0.45 | |
The 2007 Equity Incentive Plan [Member] | Minimum [Member] | |||
Weighted average exercise price per share, balance (in dollars per share) | 0.28 | 0.28 | |
Weighted average exercise price per share, Expired (in dollars per share) | 0.28 | 0.39 | |
Weighted average exercise price per share, balance (in dollars per share) | 0.28 | 0.28 | |
The 2007 Equity Incentive Plan [Member] | Maximum [Member] | |||
Weighted average exercise price per share, balance (in dollars per share) | 0.94 | 0.94 | |
Weighted average exercise price per share, Expired (in dollars per share) | 0.35 | 0.51 | |
Weighted average exercise price per share, balance (in dollars per share) | $ 0.94 | $ 1.65 | |
Non Plan [Member] | |||
Options outstanding, balance (in shares) | 20,119,207 | 20,749,583 | |
Options granted (in shares) | 105,797 | 43,956 | |
Exercise price per share, granted (in dollars per share) | $ 0.23 | ||
Options outstanding, balance (in shares) | 20,225,004 | 19,993,539 | |
Options Non-vested (in shares) | (1,050,000) | ||
Options Vested (in shares) | 19,175,004 | ||
Vested, September 30, 2022 (in dollars per share) | $ 0.38 | ||
Weighted average exercise price per share, balance (in dollars per share) | 0.41 | $ 0.41 | |
Options outstanding, Expired (in shares) | (800,000) | ||
Weighted average exercise price per share, Expired (in dollars per share) | $ 1 | ||
Weighted average exercise price per share, balance (in dollars per share) | 0.39 | 0.39 | |
Weighted average exercise price per share, granted (in dollars per share) | 0.26 | 0.23 | |
Weighted average exercise price per share, Non-vested (in dollars per share) | $ 0.45 | ||
Vested, aggregate intrinsic value | [1] | $ 274,000 | |
Exercise price per share, Expired (in dollars per share) | 1 | ||
Non Plan [Member] | Minimum [Member] | |||
Exercise price per share, balance (in dollars per share) | $ 0.17 | 0.17 | |
Exercise price per share, balance (in dollars per share) | 0.17 | 0.17 | |
Exercise price per share, Non-vested (in dollars per share) | 0.17 | ||
Exercise price per share, Vested (in dollars per share) | 0.17 | ||
Non Plan [Member] | Maximum [Member] | |||
Exercise price per share, balance (in dollars per share) | 1 | 1 | |
Exercise price per share, granted (in dollars per share) | 0.27 | ||
Exercise price per share, balance (in dollars per share) | 1 | $ 1 | |
Exercise price per share, Non-vested (in dollars per share) | 0.45 | ||
Exercise price per share, Vested (in dollars per share) | $ 1 | ||
[1]Aggregate intrinsic value based on closing common stock price of $0.27 at September 30, 2022. |
Note 6 - Warrants (Details Text
Note 6 - Warrants (Details Textual) - USD ($) | 9 Months Ended | ||
Aug. 06, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share Price (in dollars per share) | $ 0.27 | ||
Proceeds from Warrant Exercises | $ 0 | $ 60,000 | |
Class of Warrant or Right, Exercised During Period (in shares) | 416,667 | ||
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 13,568,524 | 3,932,936 | |
Warrants and Rights Outstanding, Term (Year) | 6 months | ||
Proceeds from Warrant Exercises | $ 60,000 | ||
Class of Warrant or Right, Exercised During Period (in shares) | 416,667 | ||
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | Minimum [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.19 | $ 0.14 | |
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | Maximum [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.23 | $ 0.22 | |
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 13,568,524 | 3,923,936 | |
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | Minimum [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.24 | $ 0.18 | |
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | Maximum [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.33 | $ 0.27 |
Note 6 - Warrants - Warrants Ou
Note 6 - Warrants - Warrants Outstanding (Details) - USD ($) | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | ||
Balance, outstanding (in shares) | 36,765,502 | 32,980,989 | |
Issued (in shares) | 27,137,048 | 7,865,872 | |
Expired (in shares) | (10,273,722) | (2,743,406) | |
Balance, aggregate intrinsic value | [1] | $ 2,094,000 | |
Exercised (in shares) | (416,667) | ||
Exercised (in dollars per share) | $ 0.14 | ||
Balance, outstanding (in shares) | 53,628,828 | 37,686,788 | |
Minimum [Member] | |||
Balance, outstanding, price range (in dollars per share) | $ 0.16 | $ 0.16 | |
Granted, price range (in dollars per share) | 0.19 | 0.14 | |
Expired (in dollars per share) | 0.19 | 0.12 | |
Exercised (in dollars per share) | |||
Balance, outstanding, price range (in dollars per share) | 0.14 | 0.12 | |
Maximum [Member] | |||
Balance, outstanding, price range (in dollars per share) | 1 | 1 | |
Granted, price range (in dollars per share) | 0.33 | 0.27 | |
Expired (in dollars per share) | 0.48 | 0.70 | |
Exercised (in dollars per share) | |||
Balance, outstanding, price range (in dollars per share) | 1 | 1 | |
Weighted Average [Member] | |||
Balance, outstanding, price range (in dollars per share) | 0.27 | 0.29 | |
Granted, price range (in dollars per share) | 0.23 | 0.20 | |
Expired (in dollars per share) | 0.25 | 0.59 | |
Exercised (in dollars per share) | 0.14 | ||
Balance, outstanding, price range (in dollars per share) | $ 0.26 | $ 0.27 | |
[1]Aggregate intrinsic value based on closing common stock price of $0.27 at September 30, 2022 |
Note 7 - Accounts Payable and_3
Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Corporate, Non-Segment [Member] | ||
Accounts payable and accrued expense | $ 334 | |
Accrued interest | 25 | |
Accrued payroll | 161 | |
Total accounts payable and accrued expenses | $ 520 | |
Operating Segments [Member] | Odor-No-More [Member] | ||
Accounts payable and accrued expense | $ 349 | |
Accrued interest | 25 | |
Accrued payroll | 185 | |
Total accounts payable and accrued expenses | $ 559 |
Note 8 - Noncontrolling Inter_3
Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
Mar. 03, 2022 | Jun. 30, 2020 | Dec. 30, 2015 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Apr. 08, 2022 | |
Debt Conversion, Original Debt, Amount | $ 0 | $ 328,000 | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 96,000 | $ 59,000 | $ 17,000 | $ 60,000 | $ 111,000 | ||||||||||
Stock Issued During Period, Value, New Issues | $ 1,117,000 | $ 948,000 | $ 1,202,000 | $ 123,000 | $ 1,414,000 | $ 2,106,000 | |||||||||
Clyra Medical [Member] | |||||||||||||||
Stock Issued During Period, Value, New Issues | $ 0 | $ 50,000 | |||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 310 | $ 310 | $ 310 | $ 310 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 1,403 | 2,074 | 1,403 | 2,074 | 14,004 | ||||||||||
Clyra Medical [Member] | Employees and Consultants [Member] | |||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 1 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||
Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member] | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 304,000 | $ 442,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate | 30% | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 40% | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 10 years | ||||||||||||||
Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.32% | ||||||||||||||
Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 3.83% | ||||||||||||||
Clyra Medical [Member] | Beach House Consulting, LLC [Member] | |||||||||||||||
Consulting Services, Monthly Payment | $ 23,000 | ||||||||||||||
Consulting Services, Period of Services (Year) | 4 years | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 3,639 | ||||||||||||||
Consulting Services, Three Consecutive Month Average Revenue Threshold for Consulting Fees to Accrue | $ 250,000 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 591,000 | ||||||||||||||
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 15% | 15% | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | $ 1,000,000 | |||||||||||||
Proceeds from Lines of Credit, Total | 260,000 | ||||||||||||||
Repayments of Lines of Credit | $ 97,000 | ||||||||||||||
Long-Term Line of Credit, Total | $ 163,000 | $ 163,000 | |||||||||||||
Line of Credit Facility, Covenant, Additional Draws, Maximum Percentage of Total Principal Outstanding Allowed | 50% | 50% | |||||||||||||
Line of Credit Facility, Covenant, Additional Draws, Minimum Amount Allowed | $ 200,000 | $ 200,000 | |||||||||||||
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt after the First 180 Days | 60% | 60% | |||||||||||||
Stock Issued During Period, Shares, Commitment Fee (in shares) | 323 | ||||||||||||||
Stock Issued During Period, Value, Commitment Fee | $ 70,000 | ||||||||||||||
Clyra Medical [Member] | Notes Payable, Other Payables [Member] | |||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||||||||||||
Debt Instrument, Convertible, Sale of Stock Amount | $ 5,000,000 | ||||||||||||||
Debt Instrument, Convertible, Conversion Percentage | 70% | ||||||||||||||
Conversion of Working Capital Advances into Clyra Medical Common Stock [Member] | |||||||||||||||
Debt Conversion, Original Debt, Amount | $ 633,000 | ||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 2,042 | ||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 310 | ||||||||||||||
Clyra Medical Technologies [Member] | |||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 58% | 58% |
Note 8 - Noncontrolling Inter_4
Note 8 - Noncontrolling Interest - Clyra Medical - Common Shares Outstanding (Details) - Clyra Medical Technology Inc [Member] | Sep. 30, 2022 shares |
Shares, Outstanding (in shares) | 89,071 |
Biolargo [Member] | |
Shares, Outstanding (in shares) | 51,249 |
Percent | 58% |
Sanatio [Member] | |
Shares, Outstanding (in shares) | 18,704 |
Percent | 21% |
Other [Member] | |
Shares, Outstanding (in shares) | 19,118 |
Percent | 21% |
Note 8 - Noncontrolling Inter_5
Note 8 - Noncontrolling Interest - Clyra Medical - Summary of Accounts Payable and Accrued Expenses (Details) - Clyra Medical [Member] - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Accounts payable and accrued expense | $ 202 | $ 149 |
Accrued interest | 4 | 51 |
Accrued payroll | 5 | 30 |
Total accounts payable and accrued expenses | $ 211,000 | $ 230 |
Note 9 - Business Segment Inf_3
Note 9 - Business Segment Information (Details Textual) | 9 Months Ended |
Sep. 30, 2022 | |
Number of Operating Segments | 4 |
Note 9 - Business Segment Inf_4
Note 9 - Business Segment Information - Segment Information (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Revenue | $ 1,500,000 | $ 712,000 | $ 3,786,000 | $ 1,743,000 | |
Operating loss | (943,000) | (1,455,000) | (3,973,000) | (5,013,000) | |
Interest expense | (14,000) | (26,000) | (42,000) | (208,000) | |
Research and development | (271,000) | (344,000) | (1,018,000) | (1,027,000) | |
Tangible assets | 3,442,000 | 3,442,000 | $ 2,522,000 | ||
Operating Lease, Right-of-Use Asset | 896,000 | 896,000 | 453,000 | ||
Investment in South Korean joint venture | 33,000 | 33,000 | 48,000 | ||
Total | 4,371,000 | 4,371,000 | 3,023,000 | ||
Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 33,000 | 33,000 | 48,000 | ||
Corporate, Non-Segment [Member] | |||||
Revenue | 2,000 | 0 | 4,000 | 7,000 | |
Operating loss | (783,000) | (868,000) | (2,925,000) | (2,726,000) | |
Interest expense | (6,000) | (6,000) | (18,000) | (106,000) | |
Research and development | (140,000) | (220,000) | (570,000) | (765,000) | |
Tangible assets | 785,000 | 785,000 | 690,000 | ||
Operating Lease, Right-of-Use Asset | 157,000 | 157,000 | 222,000 | ||
Total | 975,000 | 975,000 | 960,000 | ||
Corporate, Non-Segment [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 33,000 | 33,000 | 48,000 | ||
Operating Segments [Member] | Odor-No-More [Member] | |||||
Revenue | 1,199,000 | 420,000 | 2,499,000 | 1,058,000 | |
Operating loss | 400,000 | (72,000) | 418,000 | (355,000) | |
Tangible assets | 1,079,000 | 1,079,000 | 451,000 | ||
Operating Lease, Right-of-Use Asset | 0 | 0 | 0 | ||
Total | 1,079,000 | 1,079,000 | 451,000 | ||
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 0 | 0 | 0 | ||
Operating Segments [Member] | Clyra Medical [Member] | |||||
Tangible assets | 814,000 | 814,000 | 832,000 | ||
Operating Lease, Right-of-Use Asset | 0 | 0 | 0 | ||
Total | 814,000 | 814,000 | 832,000 | ||
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 0 | 0 | 0 | ||
Operating Segments [Member] | BLEST [Member] | |||||
Tangible assets | 590,000 | 590,000 | 445,000 | ||
Operating Lease, Right-of-Use Asset | 739,000 | 739,000 | 231,000 | ||
Total | 1,329,000 | 1,329,000 | 676,000 | ||
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 0 | 0 | 0 | ||
Operating Segments [Member] | BioLargo Water [Member] | |||||
Revenue | 1,000 | 2,000 | 1,000 | 9,000 | |
Operating loss | (141,000) | (156,000) | (572,000) | (461,000) | |
Research and development | (119,000) | (109,000) | (446,000) | (366,000) | |
Tangible assets | 194,000 | 194,000 | 152,000 | ||
Operating Lease, Right-of-Use Asset | 0 | 0 | 0 | ||
Total | 194,000 | 194,000 | 152,000 | ||
Operating Segments [Member] | BioLargo Water [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | 0 | 0 | 0 | ||
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member] | |||||
Revenue | 401,000 | 416,000 | 1,613,000 | 1,070,000 | |
Operating loss | (179,000) | (140,000) | (158,000) | (513,000) | |
Research and development | (100,000) | (123,000) | (288,000) | (358,000) | |
Operating Segments [Member] | Clyra Segment [Member] | |||||
Revenue | 17,000 | 9,000 | 34,000 | 114,000 | |
Operating loss | (240,000) | (219,000) | (736,000) | (958,000) | |
Interest expense | (8,000) | (20,000) | (24,000) | (96,000) | |
Research and development | (31,000) | (20,000) | (73,000) | (53,000) | |
Consolidation, Eliminations [Member] | |||||
Revenue | (120,000) | (135,000) | (365,000) | (522,000) | |
Research and development | 119,000 | $ 135,000 | 359,000 | $ 515,000 | |
Tangible assets | (20,000) | (20,000) | (47,000) | ||
Operating Lease, Right-of-Use Asset | 0 | 0 | 0 | ||
Total | (20,000) | (20,000) | (47,000) | ||
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member] | |||||
Investment in South Korean joint venture | $ 0 | $ 0 | $ 0 |
Note 10 - Commitments and Con_2
Note 10 - Commitments and Contingencies (Details Textual) - USD ($) | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Operating Lease, Expense | $ 228,000 | $ 170,000 | |
Operating Lease, Weighted Average Remaining Lease Term (Year) | 9 years | ||
Lessee, Operating Lease, Liability, to be Paid, Total | $ 1,859,000 | ||
Operating Lease, Right-of-Use Asset | $ 896,000 | $ 453,000 | |
Lessee, Operating Lease, Discount Rate | 18% | ||
Westminster, California Facility Lease [Member] | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 4 years | ||
Oak Ridge, Tennessee Facility Lease [Member] | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 10 years | ||
Operating Lease, Right-of-Use Asset | $ 443,000 | ||
Operating Lease, Liability, Total | $ 443,000 | ||
Alberta, Canada Facility Lease [Member] | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 1 year |
Note 11 - Subsequent Events (De
Note 11 - Subsequent Events (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Nov. 03, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Proceeds from Issuance of Common Stock | $ 3,267,000 | $ 4,120,000 | |||
The 2020 Unit Offering [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,766,126 | 388,889 | 13,568,524 | 3,820,436 | |
Proceeds from Issuance of Common Stock | $ 632,000 | $ 70,000 | $ 2,364,000 | $ 575,000 | |
Subsequent Event [Member] | Warrants Expiring Six Month After Investment Date [Member] | |||||
Warrants and Rights Outstanding, Term (Year) | 6 months | ||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 3,432,486 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.198 | ||||
Subsequent Event [Member] | Warrants Expiring Five Years After Investment Date [Member] | |||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 3,432,486 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.248 | ||||
Subsequent Event [Member] | The 2020 Unit Offering [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,432,486 | ||||
Proceeds from Issuance of Common Stock | $ 567,000 | ||||
Lincoln Park Capital Fund, LLC [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,440,958 | 2,917,819 | 4,353,919 | 21,444,128 | |
Proceeds from Issuance of Common Stock | $ 485,000 | $ 530,000 | $ 903,000 | $ 3,545,000 | |
Lincoln Park Capital Fund, LLC [Member] | Subsequent Event [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 479,546 | ||||
Proceeds from Issuance of Common Stock | $ 107,000 |